Psych CASC / OSCE · Psychopharmacology
Explaining tardive dyskinesia and treatment options — CASC communication station
MRCPsych/FRANZCP-style station: explain TD in plain language, balance relapse risk vs movement harm, outline monitoring (AIMS), switch options, and evidence-based VMAT2 therapy without jargon dumps.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar meeting the patient and partner in clinic after an AIMS assessment showed moderate orofacial TD.[1]
Candidate instructions. Explain tardive dyskinesia in plain language, acknowledge the link to dopamine-blocking medicines without abandoning hope, outline options (dose review, switch including possible clozapine pathway if psychosis requires ongoing treatment, VMAT2 inhibitors with trial-level evidence), and check understanding. Do not invent legal section numbers or claim SGAs never cause TD.[2][4][5]
You have read the opening of this CASC / OSCE. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]Correll CU, Citrome L Diagnostic and Treatment Fundamentals for Tardive Dyskinesia J Clin Psychiatry, 2021.PMID 34644461
- [2]Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia Am J Psychiatry, 2017.PMID 28320223
- [3]Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD) Lancet Psychiatry, 2017.PMID 28668671
- [4]Carbon M, Hsieh CH, Kane JM, Correll CU Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis J Clin Psychiatry, 2017.PMID 28146614
- [5]Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia Can J Psychiatry, 2019.PMID 30791698